Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
33.80
+2.85 (9.21%)
At close: Dec 19, 2025, 4:00 PM EST
33.55
-0.25 (-0.74%)
After-hours: Dec 19, 2025, 7:59 PM EST
Moderna Revenue
Moderna had revenue of $1.02B in the quarter ending September 30, 2025, a decrease of -45.44%. This brings the company's revenue in the last twelve months to $2.23B, down -56.07% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$2.23B
Revenue Growth
-56.07%
P/S Ratio
5.87
Revenue / Employee
$384,828
Employees
5,800
Market Cap
13.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
| Dec 31, 2019 | 60.00M | -75.07M | -55.58% |
| Dec 31, 2018 | 135.07M | -70.76M | -34.38% |
| Dec 31, 2017 | 205.83M | 97.43M | 89.88% |
| Dec 31, 2016 | 108.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MRNA News
- 2 days ago - Moderna secures up to $54.3 million funding for bird flu vaccine from global coalition - Reuters
- 2 days ago - CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - Accesswire
- 3 days ago - Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference - Accesswire
- 5 days ago - EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - Accesswire
- 18 days ago - Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 19 days ago - S&P 500 Gains and Losses Today: Moderna Falls; Synopsys Stock Climbs on Nvidia Partnership - Investopedia
- 19 days ago - FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks - Investopedia
- 19 days ago - Top Stock Movers Now: Coinbase, Robinhood, Moderna, Synopsys, and More - Investopedia